What the oncologist can learn from diabetes studies: Epidemiology, prevention, management, cure

Published:February 03, 2018DOI:https://doi.org/10.1016/j.diabres.2018.01.026

      Abstract

      Notwithstanding massive efforts and investment in improving cancer therapy, the limited progress made in reducing overall mortality has mostly been achieved through early diagnosis. Mortality rates for cardiovascular disease are in decline, a success attributable in large part to an active prevention approach coupled with identification of risk factors and biomarkers. Promising natural and synthetic molecules including numerous flavonoids have the potential to be used in diabetes care and in prevention of cardiovascular pathologies. These concepts should also be applied to cancer, the incidence of which continues to increase. In cancer chemoprevention low toxicity drugs or dietary constituents are used to prevent or delay onset of malignancy. Evidence is accumulating that cancer chemoprevention is a valuable weapon against human cancer. For example, doubling of fruit and fiber intake is associated with reduction of colorectal cancer whereas fat food consumption appears to increase malignant progression of certain tumors. Breast, colorectal and prostate cancer are the most suitable cancers for dietary prevention and scientists have strong data in these cancers at basic, translational, clinical and epidemiological levels, due to experimental evidence and the large EPIC study. Physical activity is also crucial. Yet, cancer chemoprevention research in oncology is largely underrepresented and lags far behind the efforts dedicated to therapy; it is important to close this gap. Few European phase III clinical trials are ongoing and systematic development of novel agents for cancer prevention is rare in Europe.

      Keywords

      To read this article in full you will need to make a payment

      References

        • De Flora S.
        • Quaglia A.
        • Bennicelli C.
        • Vercelli M.
        The epidemiological revolution of the 20th century.
        Faseb J. 2005; 19: 892-897
        • Roth G.A.
        • Johnson C.
        • Abajobir A.
        • Abd-Allah F.
        • Abera S.F.
        • et al.
        Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015.
        J Am Coll Cardiol. 2017; 70: 1-25
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J Clin. 2016; 66: 7-30
      1. American Cancer Society. Global Cancer Facts & Figures 3rd ed. American Cancer Society; 2015 [cited 2017]; 3rd:[available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf.

        • Blackburn E.H.
        Cancer interception.
        Cancer Prev Res (Phila). 2011; 4: 787-792
        • Sporn M.B.
        Perspective: the big C – for Chemoprevention.
        Nature. 2011; 471: S10-S11
        • Albini A.
        • Sporn M.B.
        The tumour microenvironment as a target for chemoprevention.
        Nat Rev Cancer. 2007; 7: 139-147
        • Albini A.
        • Tosetti F.
        • Li V.W.
        • Noonan D.M.
        • Li W.W.
        Cancer prevention by targeting angiogenesis.
        Nat Rev Clin Oncol. 2012; 9: 498-509
        • D'Uva G.
        • Baci D.
        • Albini A.
        • Noonan D.M.
        Cancer chemoprevention revisited: cytochrome P450 family 1B1 as a target in the tumor and the microenvironment.
        Cancer Treat Rev. 2017; 63: 1-18
        • Rossi T.
        • Gallo C.
        • Bassani B.
        • Canali S.
        • Albini A.
        • et al.
        Drink your prevention: beverages with cancer preventive phytochemicals.
        Pol Arch Med Wewn. 2014; 124: 713-722
        • Berrino F.
        • De Angelis R.
        • Sant M.
        • Rosso S.
        • Bielska-Lasota M.
        • et al.
        Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study.
        Lancet Oncol. 2007; 8: 773-783
        • Karim-Kos H.E.
        • de Vries E.
        • Soerjomataram I.
        • Lemmens V.
        • Siesling S.
        • et al.
        Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s.
        Eur J Cancer. 2008; 44: 1345-1389
        • Allemani C.
        • Coleman M.P.
        Public health surveillance of cancer survival in the United States and worldwide: the contribution of the CONCORD programme.
        Cancer. 2017; 123: 4977-4981
        • Aleksandrova K.
        • Pischon T.
        • Jenab M.
        • Bueno-de-Mesquita H.B.
        • Fedirko V.
        • et al.
        Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study.
        BMC Med. 2014; 12: 168
        • Zitvogel L.
        • Daillere R.
        • Roberti M.P.
        • Routy B.
        • Kroemer G.
        Anticancer effects of the microbiome and its products.
        Nat Rev Microbiol. 2017; 15: 465-478
        • Cuzick J.
        • Thorat M.A.
        • Bosetti C.
        • Brown P.H.
        • Burn J.
        • et al.
        Estimates of benefits and harms of prophylactic use of aspirin in the general population.
        Ann Oncol. 2015; 26: 47-57
        • Iyengar N.M.
        • Hudis C.A.
        • Dannenberg A.J.
        Obesity and cancer: local and systemic mechanisms.
        Annu Rev Med. 2015; 66: 297-309
        • Berrino F.
        Life style prevention of cancer recurrence: the yin and the yang.
        Cancer Treat Res. 2014; 159: 341-351
        • Narayan K.M.
        Type 2 diabetes: why we are winning the battle but losing the war? 2015 Kelly West award lecture.
        Diabetes Care. 2016; 39: 653-663
      2. International Diabetes Federation. IDF Diabetes Atlas – 8th ed. International diabetes federation; 2017 [cited 2017]; 8th ed. [available from: http://www.diabetesatlas.org/.

        • American Diabetes Association
        Standards of medical care in diabetes-2018.
        Diabetes Care. 2018; 41: S1-S135
        • Albini A.
        • DeCensi A.
        • Cavalli F.
        • Costa A.
        Cancer prevention and interception: a new era for chemopreventive approaches.
        Clin Cancer Res. 2016; 22: 4322-4327
        • Cuzick J.
        • DeCensi A.
        • Arun B.
        • Brown P.H.
        • Castiglione M.
        • et al.
        Preventive therapy for breast cancer: a consensus statement.
        Lancet Oncol. 2011; 12: 496-503
        • Heckman-Stoddard B.
        • Gandini S.
        • Puntoni M.
        • Dunn B.
        • DeCensi A.
        • et al.
        Repurposing old drugs to chemoprevention: the case of metformin.
        Semin Oncol. 2016; 43: 123-133
        • Choi Y.K.
        • Park K.G.
        Metabolic roles of AMPK and metformin in cancer cells.
        Mol Cells. 2013; 36: 279-287
        • Sieri S.
        • Agnoli C.
        • Pala V.
        • Grioni S.
        • Brighenti F.
        • et al.
        Dietary glycemic index, glycemic load, and cancer risk: results from the EPIC-Italy study.
        Sci Rep. 2017; 7: 9757
        • Gallo M.
        • Muscogiuri G.
        • Felicetti F.
        • Faggiano A.
        • Trimarchi F.
        • et al.
        Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes.
        Metabolism. 2018; 78: 141-154
        • Eyre H.
        • Kahn R.
        • Robertson R.M.
        Committee AAACW. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.
        CA Cancer J Clin. 2004; 54: 190-207
        • Albini A.
        • Bertolini F.
        • Bassani B.
        • Bruno A.
        • Gallo C.
        • et al.
        Biomarkers of cancer angioprevention for clinical studies.
        Ecancermedicalscience. 2015; 9: 600